Canopy Growth received EU GMP certification from RP Tuebingen, Regional Health Inspectorate of Baden-Wuerttemberg for the company’s world class cannabis cultivation facility in Kincardine, Ontario. The receipt of EU GMP certification enables Canopy Growth to continue exporting certified medical cannabis to medical markets in Europe as well as other medical cannabis markets around the world. Canopy Growth’s medical brands currently service European medical markets in Germany, Czech Republic, and Poland as well as Asia-Pacific markets including Australia & New Zealand.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CGC:
- Canopy Growth (NASDAQ:CGC) Secures Regulatory Approval for Its EU Busines
- Here’s What You Missed in Cannabis, Psychedelics This Week
- Constellation Brands reports Q2 comparable EPS ex-Canopy $3.80
- Canopy Growth price target raised to C$1.30 at Alliance Global Partners
- Rising High: Exclusive talk with medical cannabis company Clever Leaves